Document is current
Any future updates will be listed below
-
Authors
Saxena, Mansi
Anker, Jonathan F.
Kodysh, Julia
O’Donnell, Timothy
Kaminska, Anna M.
Meseck, Marcia
Hapanowicz, Olivia
Niglio, Scot Anthony
Salazar, Andres M.
Shah, Hardik R.
Kinoshita, Yayoi
Brody, Rachel
Rubinsteyn, Alex
Sebra, Robert P. https://orcid.org/0000-0001-9267-2426
Bhardwaj, Nina https://orcid.org/0000-0003-1865-4187
Galsky, Matthew D. https://orcid.org/0000-0001-7655-9378
-
Funding
Funding for this research was provided by:
Icahn School of Medicine at Mount Sinai (UL1TR004419)
- License Information
-
More Information
Article History
Received: 15 August 2024
Accepted: 2 April 2025
First Online: 9 May 2025
Competing interests
: A.M.S. is the chairman, CEO, scientific director and cofounder of Oncovir. R.P.S. is a paid consultant and equity holder at GeneDx and is the CEO and founder of Panacent Bio. N.B. has served as an advisor or board member for Carisma Therapeutics, CureVac, Genotwin, DC Prime, Rome Therapeutics and Tempest Therapeutics, has stock options in Genotwin, DC Prime and Vaccitech, has served as a consultant for Merck Research Laboratories, has received research support from Harbour Biomed Sciences and is an extramural member of the Parker Institute for Cancer Immunotherapy. M.D.G. has received research funding from Bristol Myers Squibb, Novartis, Dendreon, AstraZeneca, Merck and Genentech and has served as a consultant to Bristol Myers Squibb, Merck, Genentech, AstraZeneca, Pfizer, EMD Serono, SeaGen, Janssen, Numab, Dragonfly, GlaxoSmithKline, Basilea, UroGen, Rappta Therapeutics, Alligator, Silverback, Fujifilm, Curis, Gilead, Bicycle, Asieris, Abbvie and Analog Devices. The other authors declare no competing interests.
